Stephen Colagiuri Named New Editor-In-Chief
Diabetes Research and Clinical Practice
Oxford, UK, 10 April 2008 - Stephen Colagiuri has been named the new Editor-in-Chief of Diabetes Research and Clinical Practice, effective April 1, 2008. Professor Colagiuri takes over from Professor Nigishi Hotta who has been acting as Editor-in-Chief since 2004 and now becomes an Honorary Editor-in-Chief of Diabetes Research and Clinical Practice, the official journal of the International Diabetes Federation/Western Pacific Region.
“It is an honor to take on this role and I look forward to the challenge and to building on the excellent work of Professor Hotta”, commented Professor Colagiuri.
Stephen Colagiuri is Professor of Metabolic Health at the University of Sydney. His research interests focus on development and implementation of evidence-based guidelines, cardiometabolic risk assessment, diabetes screening and prevention, the glycemic index, and economic aspects of diabetes and obesity. He has over 100 publications in scientific journals and books, and is a past President of the Australian Diabetes Society.
He is also a member of the Diabetes Expert Advisory Committee of the Commonwealth Department of Health and Aged Care, chair of the International Diabetes Federation Global Guideline Working Group, and an advisor on diabetes to the World Health Organization.
# # #
About Diabetes Research and Clinical Practice
Diabetes Research and Clinical Practice is devoted to covering original research articles and high-quality reviews in areas of growing interest in the field of epidemiology, experimental biology, nutrition and clinical practice. The purpose of the journal is to encourage interdisciplinary discussion of topics which are relevant to the fields of diabetology and medical science on an international scale, with a particular focus on those that are or will be clinically relevant.
Diabetes Research and Clinical Practice is the official journal of the International Diabetes Federation, Western Pacific Region.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.
+44 1865 843786